Abstract: In an embodiment, cross sectional image storage stores a cross sectional image group including multiple cross sectional images each of which is associated with time. Phase image storage stores a phase image group including multiple phase images each of which is associated with time. Blood flow information storage stores a blood flow information group including multiple blood flow information each of which is related to blood flow in a blood vessel of the living body and is associated with time. Display synchronously displays a cross sectional image included in the cross sectional image group and a phase image included in the phase image group using time associated with the cross sectional image and the phase image, and displays a blood flow image that expresses multiple blood flow information. The display performs the same change as the change to the cross sectional image, the phase image and the blood flow image.

Abstract: Disclosed is a water-insoluble polymeric iron chelating agent having a polymer backbone and an aromatic ring attached to the polymer backbone through an —NH—CH2— bond, wherein the aromatic ring has one or two first functional groups in the form of hydroxyl group and one or two second functional groups located at the ortho position with respect to the first functional group; and wherein the second functional group is —OH, —COOH, or a group represented by formula (I) wherein A represents —CH3, —CH2—CH3, —CH2—C6H5, —CH2—C5H4N or —CH2—COOH and B represents —CH2—COOH. The water-insoluble polymeric iron chelating agent of the present invention offers the advantages of being capable of selectively chelating iron ions, particularly biologically unstable iron, and being insoluble in water, and moreover not being incorporated in metabolic processes in vivo.

Abstract: An optical system splits light into signal light and reference light and detects interference light between scattered light of signal light from living body and reference light. A scanner performs first scan in which first cross section that intersects interested blood vessel is repeatedly scanned with signal light. An image forming part forms first cross sectional image expressing chronological variation of morphology of first cross section and phase image expressing chronological variation of phase difference based on detection results of interference light acquired during first scan. A blood vessel region specifying part specifies blood vessel region corresponding to interested blood vessel for first cross sectional image and phase image. A blood flow information generator generates blood flow information related to interested blood vessel based on blood vessel region of first cross sectional image and chronological variation of phase difference within blood vessel region of phase image.

Abstract: In an embodiment, cross sectional image storage stores a cross sectional image group including multiple cross sectional images each of which is associated with time. Phase image storage stores a phase image group including multiple phase images each of which is associated with time. Blood flow information storage stores a blood flow information group including multiple blood flow information each of which is related to blood flow in a blood vessel of the living body and is associated with time. Display synchronously displays a cross sectional image included in the cross sectional image group and a phase image included in the phase image group using time associated with the cross sectional image and the phase image, and displays a blood flow image that expresses multiple blood flow information. The display performs the same change as the change to the cross sectional image, the phase image and the blood flow image.

Abstract: In an embodiment, cross sectional image storage stores a cross sectional image group including multiple cross sectional images each of which is associated with time. Phase image storage stores a phase image group including multiple phase images each of which is associated with time. Blood flow information storage stores a blood flow information group including multiple blood flow information each of which is related to blood flow in a blood vessel of the living body and is associated with time. Display synchronously displays a cross sectional image included in the cross sectional image group and a phase image included in the phase image group using time associated with the cross sectional image and the phase image, and displays a blood flow image. The display performs the same change as the change to the change operation to the cross sectional image, the phase image and the blood flow image.

Abstract: An optical system splits light into signal light and reference light and detects interference light between scattered light of signal light from living body and reference light. A scanner performs first scan in which first cross section that intersects interested blood vessel is repeatedly scanned with signal light. An image forming part forms first cross sectional image expressing chronological variation of morphology of first cross section and phase image expressing chronological variation of phase difference based on detection results of interference light acquired during first scan. A blood vessel region specifying part specifies blood vessel region corresponding to interested blood vessel for first cross sectional image and phase image. A blood flow information generator generates blood flow information related to interested blood vessel based on blood vessel region of first cross sectional image and chronological variation of phase difference within blood vessel region of phase image.

Abstract: An image processing unit of an image processing apparatus includes: a pixel value acquiring part that acquires pixel values of new pixels obtained by increasing resolution of a first image, using pixel values of multiple original pixels, of the first image, around a position at which each of the new pixels is disposed; a representative value acquiring part that acquires a representative value of the pixel values of the multiple new pixels arranged in an area in which each of the original pixels is disposed; a correction value acquiring part that acquires a correction value using the pixel value of each of the original pixels and the representative value; and a pixel value correcting part that corrects the pixel value of each of the original pixels using the correction value. The image processing unit performs correction processing for correcting the original pixels is repeated once or at least twice.

Abstract: An image processing unit of an image processing apparatus includes: a pixel value acquiring part that acquires pixel values of new pixels obtained by increasing resolution of a first image, using pixel values of multiple original pixels, of the first image, around a position at which each of the new pixels is disposed; a representative value acquiring part that acquires a representative value of the pixel values of the multiple new pixels arranged in an area in which each of the original pixels is disposed; a correction value acquiring part that acquires a correction value using the pixel value of each of the original pixels and the representative value; and a pixel value correcting part that corrects the pixel value of each of the original pixels using the correction value. The image processing unit performs correction processing for correcting the original pixels is repeated once or at least twice.

Abstract: The present invention relates to a method of safely and simply inducing differentiation of mononuclear cells into cells that promote neovascular stabilization and maturation, and lead to recovering from ischemia or tissue repair. The cells according to the present invention are obtained by inducing differentiation of a mononuclear cell by culturing the mononuclear cell in a medium (particularly a serum-free medium) containing one or more selected from vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), thrombopoietin (TPO), granulocyte-colony stimulating factor (G-CSF) and FMS-like tyrosine kinase 3 ligand (FLT3L), and collecting a cell population expressing CD11b.

Abstract: An image processing apparatus includes: a region-of-interest setting information storage unit in which region-of-interest setting information for setting one or more regions of interest in a specified cross-sectional image is stored; an evaluation value acquiring unit that acquires, using measured values, an evaluation value for evaluating a region of interest in the specified cross-sectional image, for each region of interest indicated by the region-of-interest setting information, and acquires, using measured values, a related evaluation value for evaluating a region in one or more cross-sectional images other than the specified cross-sectional image, for each region corresponding to each region of interest indicated by the region-of-interest setting information; and an output unit that outputs the acquired evaluation value and related evaluation value in association with the specified cross-sectional image corresponding to the evaluation value and the cross-sectional image corresponding to the related eval

Abstract: With a terminal apparatus that includes an authentication method deciding unit that selects one of two or more authentication methods according to acquired position information, an authentication screen output unit that outputs a screen corresponding to the one authentication method, an accepting unit that accepts authentication information that is input on that screen, an authentication information sending unit that sends an authentication method identifier that identifies an authentication method and the authentication information to a server, an output information receiving unit that receives, from the server, one or more pieces of output information corresponding to the authentication method identification information in the case of success of authentication, and an output information output unit that outputs output information, information necessary for medical practice can be acquired while appropriately securing the privacy of a patient.

Abstract: Disclosed is a water-insoluble polymeric iron chelating agent having a polymer backbone and an aromatic ring attached to the polymer backbone through an —NH—CH2— bond, wherein the aromatic ring has one or two first functional groups in the form of hydroxyl group and one or two second functional groups located at the ortho position with respect to the first functional group; and wherein the second functional group is —OH, —COOH, or a group represented by formula (I) wherein A represents —CH3, —CH2—CH3, —CH2—C6H5, —CH2—C5H4N or —CH2—COOH and B represents —CH2—COOH. The water-insoluble polymeric iron chelating agent of the present invention offers the advantages of being capable of selectively chelating iron ions, particularly biologically unstable iron, and being insoluble in water, and moreover not being incorporated in metabolic processes in vivo.

Abstract: An anticancer therapy using autologous cells or the like, which induces the regression of cancer or has favorable drug delivery effects and brings about reduction or withdrawal of a hypoxic region(s) in tumor is provided. Transplantation of endothelial progenitor cells, via intravenously or other methods leads to tumor growth inhibition, an increase of the vascular density with an enlargement of the vascular diameter, and reduction of a hypoxic region(s) in the tumor. Allogeneic transplantation of endothelial progenitor cells may be achieved to secure the cells for the therapy, however, autologous transplantation of endothelial progenitor cells from cancer patients would be desirable to evade rejection. When autologous cells are used, mononuclear cells are separated from the peripheral blood or bone marrow of the patient and cultured using an endothelial differentiation medium containing cytokines such as VEGF to obtain adherent cells, which can then be collected and used as endothelial progenitor cells.

Abstract: The present invention provides an intestinal tract protective agent comprising a polyphosphoric acid or a pharmaceutically acceptable salt thereof as an active ingredient.